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CLINICAL INVESTIGATION
Immunohistochemical detection of advanced glycation end
products in dialysis-related amyloidosis
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Immunohistochemical detection of advanced glycation end products in
dialysis-related amyloidosis. 32-Microglobulin (132m) isolated from the
amyloid deposits in patients with dialysis-related amyloidosis (DRA) has
been demonstrated to be modified with advanced glycation end products
(AGE). We produced a monoclonal anti-AGE antibody which localized
AGE to amyloid deposits in patients with DRA by immunohistochemistry.
The connective tissues in the carpal tunnel were obtained from surgical
specimens in six patients with DRA. AGE were localized to the j32m-
positive amyloid deposits in these patients using the monoclonal anti-AGE
antibody. AGE were also detected in infiltrating cells surrounding the
amyloid deposits. The AGE-positive cells were identified as macrophages,
since they showed positive staining with anti-CD68 antibody. In conclu-
sion, AGE were demonstrated by immunohistochemical technique to be
present in both /32m-positive amyloid deposits and surrounding macro-
phages in patients with DRA.
Dialysis-related amyloidosis (DRA) is a serious complication in
patients maintained on long-term dialysis [1]. Carpal tunnel
syndrome (CTS), cystic lesions of long bones, particularly in the
femoral and humeral heads, destructive spondyloarthropathy, and
diffuse arthritis and periarthritis of the scapulohumeral region are
seen with increasing frequency as a consequence of amyloid
deposition in these patients. The major component of amyloid has
been demonstrated to be /32-microglobulin (p2m) [2—5], a
n-pleated protein sheet that is produced in the greatest amounts
by cells of the lymphoid system where it constitutes a portion of
the HLA antigen. Serum levels of 2m in dialysis patients are
markedly increased as a result of diminished glomerular filtration.
However, there is no significant correlation between the serum
level of 2m and the occurrence of DR.A [6].
Recently, advanced glycation end products (AGE) have been
demonstrated in f32m isolated from amyloid deposits in patients
with CTS [71. AGE-/32m has also been detected in the urine and
sera of these patients but not in that of healthy subjects. Further
study has demonstrated that AGE-j32m may be involved in the
pathogenesis of DRA by stimulating the chemotaxis of mono-
cytes, the secretion of IL-1f3 and TNF-a from macrophages, and
the subsequent synthesis of collagenase in synovial cells [81.
Glucose reacts nonen.zymatically with protein amino groups to
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initiate nonenzymatic glycation. This process begins with the
conversion of reversible Schiff base adducts to stable, covalently
bound Amadori rearrangement products. Some Amadori prod-
ucts undergo further dehydration and rearrangements to form
AGE, which are characterized by: (1) browning, (2) fluorescence,
(3) cross linking, and (4) biological recognition through receptors
specific for AGE on macrophages [9, 101. The entire process is
called the Maillard reaction. The chemical modification of long-
lived proteins, such as lens crystalline and collagen, via the
Maillard reaction, has been postulated to contribute to the
complications associated with aging and diabetes mellitus such as
cataracts, nephropathy, neuropathy and vascular diseases [11—13].
The in vivo presence of AGE has been demonstrated in human
lens crystalline [14], human hemoglobin [15], 132m [7], -amyloid
peptide and tau protein [16—18]. Several compounds such as
2-(2-furoyl)-4(5)-(2-furanyl)-1H-imidazole (FF1) [19], pyrraline
[20], pentosidine [21] and crosslines [22] have been proposed as
potential candidates for AGE. However, FF1 [23] has been
excluded, and pyrraline [24] has been reported not to be AGE.
AGE-f32m has been isolated from the amyloid tissue of patients
with DRA and characterized by immunochemical methods [7]. Its
localization has not been demonstrated by immunohistochemical
techniques. The localization of AGE in the amyloid deposits
related to DRA was pursued using a monoclonal anti-AGE
antibody. In this study we have demonstrated for the first time
that AGE are localized to the /32m-positive amyloid. Further, the
localization of AGE in the other forms of amyloid such as AL or
AA amyloid, and in the chronic inflamed tissue, was studied to
know if the association of AGE with /32m-amyloid is specific for
this form of amyloid.
Methods
Patients and tissue preparation
Samples of carpal tunnel connective tissue were obtained
during surgical operation from six patients with DRA (Table 1).
The tissue specimens were divided into thin sections. These
sections were then fixed in 20% phosphate-buffered formalde-
hyde, dehydrated in a graded series of ethanol, and embedded in
paraffin. Amyloid deposits were identified by Congo-red staining.
To study if AGE are involved in the other forms of amyloid and
chronic inflamed tissue, kidneys containing amyloid deposits were
obtained by autopsy from four patients with AL amyloidosis
(65-year-old male with primary amyloidosis, 54-year-old male with
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Table 1. Profile of patients with DRA and immunohistochemical detection of AGE in amyloid of synovium
Patient Age Sex
Duration
on HD
years
Cause of
renal
failure
Source of
synovium
Serum
creatinine
mg/di
Serum
32m
pg/mi
Staining of amyloid in synovium
Congo red 32m AGE
K.N. 54 M 20.8 CGN r-CT 12.7 34.7 +++ +++ ++
K.S. 56 F 12.6 CGN 1-CT 7.8 27.5 ++ +++ ++
S.M. 46 M 17.1 CGN 1-CT 12.4 30.3 +++ +++ ++
K.S. 49 F 15.9 CGN r-CT 11.3 35.6 +++ +++ ++
TI. 49 M 23.2 CGN 1-CT 9.1 24.1 +++ +++ ++
Y.K. 61 F 14.8 CGN 1-CT 8.4 24.2 ++ +++ +
Abbreviations are: M, male; F, female; CGN, chronic glomerulonephritis; r, right; 1, left; CT, carpal tunnel.
primary amyloidosis, 59-year-old female with multiple myeloma of
IgAA type, and 66-year-old female with multiple myeloma of IgGi
type), and three patients with AA amyloidosis (74-year-old female
with rheumatoid arthritis, 58-year-old female with rheumatoid
arthritis, and 60-year-old female with systemic lupus erythemato-
sus). Synovium tissue specimens of knee joints were obtained by
biopsy from four patients with rheumatoid arthritis (65-year-old
female, 56-year-old female, 44-year-old female, and 67-year-old
male). The tissue specimens were fixed, dehydrated and embed-
ded as described above.
In vitro preparation of AGE-modified proteins and lysine
AGE-modified keyhole limpet hemocyanin (AGE-KLH),
AGE-modified human serum albumin (AGE-HSA), AGE-modi-
fied bovine serum albumin (AGE-BSA), AGE-modified f32m, and
AGE-modified lysine were produced by incubating KLH (20
mg/ml), HSA (100 mg/ml), BSA (100 mg/ml), f32m (100 g/ml) or
lysine (1 M) (all from Sigma Chemical Company, St. Louis, MO,
USA), respectively, at 37°C for one month (or 3 months for KLH)
with 1 M glucose in 200 mrvi phosphate buffer (PB), pH 7.4,
containing 0.02% NaN3.
Production of monoclonal anti-AGE antibody
Six-week-old female BALB/c mice were given intraperitoneal
injections of AGE-KLH (0.1 mg) with Freund's complete adju-
vant. The equivalent amount of AGE-KLH with Freund's incom-
plete adjuvant was injected, likewise, four times at two week
intervals. Finally, AGE-KLH (0.05 mg) was intravenously admin-
istered to the mice. Fusion of the splenic cells with myeloma cells
and their culture were performed according to the method of
Kohler and Milstein [25].
Hybridoma cells secreting anti-AGE antibodies were screened
by sandwich enzyme-linked immunosorbent assay (ELISA) using
rabbit anti-mouse immunoglobulins (Dakopatts, Denmark)
coated microplate, AGE-HSA, and peroxidase-labeled rabbit
anti-HSA immunoglobulins (Dakopatts). Supernatant isolated
from the culture (0.1 ml) was incubated at room temperature for
1.5 hours on a microplate coated with rabbit anti-mouse immu-
noglobulins. After washing with phosphate buffered saline (PBS)
containing 0.05% Tween 80 and 0.03% Triton X-405, 0.1 ml of
AGE-HSA (10 sg/ml) were added into the microplate, followed
by incubation at room temperature for 1.5 hours. After washing
the microplate with PBS containing 0.05% Tween 80 and 0.03%
Triton X-405, peroxidase-conjugated rabbit anti-HSA immuno-
globulins was added to the plate, followed by incubation at room
temperature for 1.5 hours. After washing with PBS containing
0.05% Tween 80 and 0.03% Triton X-405, 0,1 ml of o-phe-
nylenediamine hydrochloride (0.52 mg/ml) containing 0.02%
H202 was added to the microplate, and then incubated at room
temperature for 0.5 hour. The reaction was terminated with 0.8 M
H2S04. The absorption at 492 nm was measured using 620 nm as
the control.
Anti-AGE antibody was purified by injecting cloned hybridoma
cells secreting anti-AGE antibody into 8-week-old female BALB/c
mice. Ascitic fluid collected after two weeks was fractionated,
dialyzed and applied to diethylaminoethyl (DEAE)-cellulose col-
umn chromatography.
Characterization of monoclonal anti-AGE antibody
The reactivity of the produced monoclonal antibodies with
reduced AGE-HSA, AGE-BSA, AGE-f32m or AGE-lysine was
measured using a competitive ELISA. The sample of solution (25
pJ) or standard AGE-HSA (0 to 1000 g/ml) was incubated at
room temperature for one hour in a AGE-HSA-coated micro-
plate with PBS (50 1.d) containing 0.25% BSA and peroxidase-
conjugated anti-AGE antibody (AG-b). After washing four times
with PBS, 0.087% o-phenylenediamine hydrochloride containing
0.02% H202 (100 1.d) was added to the microplate. The reaction
was terminated with 0.8 M H2S04 (100 il). The absorption at 492
nm was measured using 620 nm as the control.
Figure 1 illustrates the characterization of a monoclonal anti-
AGE antibody (AG-b). Subclass of the antibody was IgG2,K.
That the anti-AGE antibody was unreactive with early Amadori
glycation products, was confirmed by the observation that sodium
borohydride reduction, which alters the Amadori product epitope,
did not affect the reactivity of the antibody to AGE-HSA.
Moreover, the anti-AGE antibody did not react with caproyl
pyrraline. Hydrolysis of AGE-HSA and AGE-BSA with 6 M HC1
at 110°C for 24 hours markedly reduced their reactivity to the
anti-AGE antibody. This finding suggests that the anti-AGE
antibody does not react with pentosidine because pentosidine is
stable under acid hydrolysis. The anti-AGE antibody (1 mg/mI)
was stored in 10 ml PBS, pH 7.4, containing 0.05% NaN3 at 4°C.
Immunohistochemical detection of AGE and f32in
AGE and /32m in the amyloid deposits were studied using the
peroxidase-antiperoxidase (PAP) method with monoclonal anti-
AGE antibody and anti-human 132m antibody. The tissue speci-
mens were divided into thin sections (3 j.tm thick) which were then
deparaffinized. The sections were washed with PBS for 20 min-
utes. Endogenous peroxidase activity was blocked by incubating
the sections with 0.3% H202 in methanol for 5 to 30 minutes. The
sections were washed with PBS and then incubated with 5%
normal rabbit serum in PBS at 37°C for 20 minutes. After
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Fig. 1. Competitive ELISA demonstrating the specificity of the monoclonal
anti-AGE antibody (AG-b). The anti-AGE antibody reacted with AGE-
HSA (-S-) reduced AGE-HSA (-X-), AGE-BSA (-A-), AGE-f32m (-U-)
and AGE-lysine (-•-), but did not react with HSA (-0-), BSA (-A-), f32m
(-0-), or lysine (-0-). Thus, the antibody recognizes a common epitope of
AGE.
removing the normal rabbit sera, the sections were incubated with
either monoclonal anti-AGE antibody (AG-b), rabbit polyclonal
anti-human f32m antibody (Zymed Laboratories, San Francisco,
CA, USA), or monoclonal anti-CD68 antibody (Dakopatts) at 4°C
overnight. The sections were washed with PBS and incubated with
the second antibody, rabbit polyclonal anti-mouse immunoglobu-
lin antibody (Zymed Laboratories), at 37°C for 60 minutes. After
washing thrice with PBS, the sections were incubated with mouse
polyclonal PAP complex (Nordic Immunological Laboratories,
Netherlands) at 37°C for 30 to 60 minutes. After washing thrice
with PBS, the reaction was completed by the addition of diami-
nobenzidine (DAB)-H202 solution for 5 to 30 minutes. After
washing with PBS, the slides were then counterstained with
hematoxylin.
Control samples to which the primary antibody had not been
applied, were processed simultaneously. The same concentration
of primary anti-AGE antibody was incubated with AGE-BSA (1
mg/ml) or AGE-KLH (1 mg/mI) at 37°C for 90 minutes. After
centrifuging the mixture at 10,000 g for 30 minutes, the superna-
tant was used as the primary antibody solution followed by the
usual PAP method.
In these experiments, the slides were read by a pathologist in a
blinded fashion, and scored on a semiquantitative scale (zero to
+ + +) according to the degree of positive staining.
Results
Figure 2 demonstrates the presence of amyloid deposits in
carpal tunnel synovium from a patient with DRA (S.M.). Amyloid
deposits that stained with Congo red, also reacted with anti-f32m
antibody, indicating that the amyloid deposits were composed of
2m. Congo red-positive amyloid tissue revealed characteristic
birefringence with polarizing microscopy. Immunostaining with
anti-AGE antibody correlated with AGE localized to those areas
stained with Congo red and anti-132m antibody.
Figure 3 also demonstrates amyloid deposition in carpal tunnel
synovium from the same patient. Immunostaining with anti-2m
antibody revealed /32m-amyloid localized to the infiltrating cells.
Immunostaining with anti-AGE antibody demonstrated the pres-
ence of AGE in the /'32m-amyloid deposits and, more notably, in
the infiltrating cells surrounding these amyloid deposits. However,
AGE in the cells did not react with the anti-/32m antibody.
Immunostaining of tenosynovium obtained from this patient
demonstrated that the AGE-positive cells were macrophages,
since they also stained positively with anti-CD68 antibody (Fig. 4).
Figure 5 demonstrates amyloid deposits in carpal tunnel syno-
vium from another patient with DRA (K.S.). Congo red-positive
deposits stained with anti-/32m antibody, indicating that the
amyloid deposits were composed of f32m. Immunostaining with
the anti-AGE antibody demonstrated the presence of AGE
localized within the areas corresponding to those of Congo red
positive and anti-J32m antibody positive staining.
Table 1 summarizes the results of the immunohistochemical
detection of AGE in amyloid deposits isolated within the syno-
vium from six patients with DRA. Each patient sample had
amyloid deposits that stained with the anti-AGE antibody,
thereby demonstrating the presence of AGE in J32m-amyloid.
Control experiment, in which the primary antibody was not used,
and absorption experiments in which the primary anti-AGE
antibody was preincubated with AGE-BSA or AGE-KLH, re-
vealed an absence of staining in the amyloid deposits.
Immunostaining with the anti-AGE antibody demonstrated
that AGE were not localized to Congo red-positive amyloid
deposits in kidneys obtained from four patients with AL amyloid-
osis and three patients with AA amyloidosis. It also demonstrated
that AGE were not localized to collagen in synovium tissue
specimens obtained from four patients with rheumatoid arthritis.
Small artery walls that are negative to Congo red staining, in the
carpal tunnel synovium tissue from the patients with DRA
scarcely reacted with anti-AGE antibody.
Discussion
Our results demonstrate immunohistochemically that AGE are
localized to 2m-positive amyloid deposits in the synovium of
patients with DRA. More notably, AGE are detectable in mac-
rophages surrounding these tissues. However, AGE in the mac-
rophages do not stain with anti-j32m antibody. This lack of 132m in
the AGE-positive macrophages suggests that AGE-j32m is de-
graded to AGE-peptide or AGE by the macrophages after its
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Fig. 2. Light and polarizing micrographs of amyloid tissue in carpal tunnel obtained from S.M. A. Congo red staining (x40). B. Polarizing microscopy of
Congo-red staining (x40). C. Staining with anti-2m antibody (PAP method, X40). D. Staining with anti-AGE antibody (AG-b) at 0.21 j.tg/ml (PAP
method, X40). AGE were localized to the areas that stained with Congo red and anti-132m antibody and revealed characteristic birefringence,
demonstrating the presence of AGE in 132m-amyloid deposits. The infiltrating cells surrounding the amyloid deposits also reacted with anti-AGE
antibody. Publication of this figure in color was made possible by a grant from Maruko Pharmaceutical Co., Aichi, Japan.
endocytosis through the AGE receptors. However, it cannot be
excluded that AGE-laden macrophages carry AGE to amyloid
deposits and AGE released from dying macrophages bind to
f32m-amyloid.
The monoclonal anti-AGE antibody developed by us recognizes
a common epitope of AGE, and reacted with acidic f32m isolated
from amyloid deposits in long-term hemodialysis patients by
Western blotting after two-dimensional electrophoresis. The as-
sociation of AGE with 2m-amyloid may be specific for this form
of amyloid, because AGE were not demonstrated by the present
method to be localized to AL or AA amyloid deposits. AGE were
also not localized to collagen in synovium tissue of osteoarthritic
joints associated with rheumatoid arthritis. Small artery walls
from the patients with DRA scarcely reacted with AGE. Thus, the
presence of AGE seems to be specific for f32m-amyloid and is
uncommon in the chronic inflamed collagen tissue.
Scavenger receptors for the uptake of AGE-modified proteins
are present on macrophages/monocytes [9, 10], endothelial cells
[26] and renal mesangial cells [271. Membrane-associated recep-
tors, comprising at least a 90 and a 60 kD protein specificity for
the ingestion and elimination of AGE-modified protein, have
been identified on both murine peritoneal macrophages and
human monocytes. AGE-modified proteins are chemotactic for
monocytes, and the receptor-mediated endocytosis of AGE-
modified proteins by monocytes triggers the synthesis and release
of cytokines, in particular interleukin-1f3 (IL-1/3) and tumor
necrosis factor-a (TNF-a) [8, 28]. TNF-a induced by the uptake
of AGE-modified proteins up-regulates the AGE-receptor
function in an autocrine manner [29]. Our demonstration of
AGE within macrophages surrounding the amyloid deposits
suggests that the binding, endocytosis and subsequent degra-
dation of AGE-modified /32m-amyloid by macrophages occur
via their AGE receptors. This receptor-mediated uptake of
AGE by macrophages activates the macrophages to secrete
IL-113 and TNF-a, which then stimulate synovial cells to
promote the release of collagenase [81. Thus, AGE-modified
amyloid may be involved in the pathogenesis of DRA through
macrophage activation.
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Fig. 3. Photomicrographs of amyloid tissue in the carpal tunnel obtained from S.M. A. Staining with anti-/32m antibody (PAP method, X 160). B. Staining
with anti-AGE antibody (AG-b) at 0.21 tg/ml (PAP method, X 160). Immunostaining with anti-2m antibody detected 32m-amyloid deposits localized
around infiltrating cells. Immunostaining with anti-AGE antibody demonstrated the presence of AGE in the J32m-amyloid deposits and, more notably,
in the infiltrating cells surrounding the amyloid deposits. The arrows indicate the presence of AGE in the infiltrating cells. However, intracellular AGE
did not react with anti-!32m antibody. Publication of this figure in color was made possible by a grant from Maruko Pharmaceutical Co., Aichi, Japan.
AGE are produced nonenzymatically via the Maillard reaction
involving the interaction of protein amino groups with glucose.
Thus, the presence of in vivo AGE modification has been dem-
onstrated in ciystalline [14], hemoglobin [15], 132m [7], -amyloid
peptide and tau protein [16—181, indicating the involvement of
AGE modification in conditions such as aging, diabetic hypergly-
cemia, DRA and Alzheimer's disease, respectively. The accumu-
lation of AGE is caused either by increased production (aging,
diabetes mellitus, and Alzheimer's disease) or decreased removal
(uremia). f32m, which is normally catabolized in the kidneys,
markedly accumulates in the blood of uremic patients. The longer
half life of 2m in these patients may promote AGE-modification.
In fact, AGE-132m has been identified in the sera and urine of the
uremic patients [7]. AGE-132m, which has the tendency to cross
link and polymerize, may deposit in joint structures (particularly
bones) forming amyloid deposits. Another possible mechanism to
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Fig. 4. Photomicrographs of tenosynovium in the caipal tunnel from S.M A. Staining with anti-AGE antibody (AG-b) at 0.21 sg/mI (PAP method, X80).
B. Staining with anti-CD68 antibody (PAP method, x80). Immunostaining with anti-AGE antibody and anti-CD68 antibody demonstrated that the
AGE-positive cells were macrophages, since they reacted with anti-CD68 antibody. Publication of this figure in color was made possible by a grant from
Maruko Pharmaceutical, Aichi, Japan.
explain the formation of AGE-modified 32m-amyloid is AGE-
modification after deposition of 2m and the subsequent forma-
tion of amyloid. Once amyloid is formed, it is difficult to degrade.
Moreover, it may react with glucose and undergo AGE modifica-
tion even in the presence of normoglycemia. Further study will be
required to clarify the exact mechanism for the formation of
AGE-modified f32m-amyloid.
This is the first immunohistochemical study that demonstrates
the localization of AGE in areas corresponding to Congo-red-
positive and f32m-positive amyloid deposits of patients with DRA.
Moreover, AGE were present in the macrophages surrounding
these amyloid deposits. The association of AGE may be specific
for 132m-amyloid, and is uncommon in the other forms of amyloid
(AL or AA) and the chronic inflamed collagen tissue. AGE
modification of 132m-amyloid may occur in 32m-amyloid deposits
which have existed for months to years. Alternatively, AGE-J32m
seeds may accelerate the aggregation of soluble J32m and promote
further deposition of f32m amyloid within tissues.
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Fig. 5. Photomicrographs of amyloid deposits in
carpal tunnel obtained from KS. A. Congo red
staining. B. Staining with anti-f32m antibody
(PAP method x200). C. Staining with anti-
AGE antibody (AG-b) at 0.21 tg/m1 (PAP
method X200). Congo red-positive amyloid
deposits reacted with anti-132m antibody and
anti-AGE antibody, demonstrating the presence
of AGE in the 32m-amyloid deposits.
Publication of this figure in color was made
possible by a grant from Maruko
Pharmaceutical, Aichi, Japan.
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